Waters and Tecan Sign Agreement for Clinical Assay Platform
News Jan 18, 2012
Waters Corporation and Tecan Group will combine Tecan's Freedom EVO® liquid handling platform with Waters® ACQUITY® TQD liquid chromatograph/mass spectrometer to automate sample preparation.
Waters will combine the technologies from both companies into a single, fully-supported analytical system solution that helps laboratories increase assay throughput and efficiency, improve profitability, and drive down overall assay costs. The firms announced the agreement at the annual Mass Spectrometry: Applications for the Clinical Laboratory (MSACL) meeting January 14 – 18 at which Waters will be exhibiting a number of its LC-MS based products including those for the therapeutic drug monitoring of the immunosuppressant drug Tacrolimus®. Waters will also present a variety of technical workshops and scientific posters at this year's conference.
"The multi-step process of preparing samples for LC/MS/MS analyses remains a significant bottleneck and an opportunity for improvement in many laboratories. If there is one thing laboratory managers consistently ask for, it's better, more automated sample preparation and analysis," said Patrick Martell, Clinical Marketing Director, Waters Division. "Combining sample preparation and analysis in a single unified platform facilitates the entire assay process and streamlines analyses significantly. By lowering assay costs and bringing a greater consistency to test results, laboratories can offer clients a higher level of service and responsiveness."